GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells

Cancer Biology and Therapy

Volumn 9, Issue 8, 2010, Pages 640-650

  Shi, Xianping ^a   Wang, Deping ^b   Ding, Ke ^b   Lu, Zhongzheng ^a   Jin, Yanli ^a   Zhang, Jin ^b   Pan, Jingxuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

Cell cycle; GDP366; Mitotic catastrophe; Op18 stathmin; Polyploidy; Senescence; Survivin

Indexed keywords

GDP 366; MESSENGER RNA; PROTEIN INHIBITOR; PROTEIN P21; PROTEIN P53; STATHMIN; SURVIVIN; TELOMERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL AGING; CHROMOSOMAL INSTABILITY; COLON TUMOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; POLYPLOIDY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; TUMOR GROWTH;

EID: 77953712587     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.8.11269     Document Type: Article

References (35)

1. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999; 1:461-6.
2. Miller LK. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol 1999; 9:323-8.
3. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14:5000-5.
4. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13:239-52.
5. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396:580-4.
6. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8:61-70.
7. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007; 8:798-812.
8. Carter BZ, Mak DH, Schober WD, Cabreira-Hansen M, Beran M, McQueen T, et al. Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells. Blood 2006; 107:1555-63.
9. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, et al. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 2009; 15:1326-34.
10. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27:4481-6.
11. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, et al. YM155, a novel smallmolecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67:8014-21.
12. Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 2008; 7:2736-45.
13. Fukuda S, Singh P, Moh A, Abe M, Conway EM, Boswell HS, et al. Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. Blood 2009; 114:394-403.
14. Marklund U, Larsson N, Gradin HM, Brattsand G, Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J 1996; 15:5290-8. (Pubitemid 26336212)
15. Sobel A, Tashjian AH Jr. Distinct patterns of cytoplasmic protein phosphorylation related to regulation of synthesis and release of prolactin by GH cells. J Biol Chem 1983; 258:10312-24.
16. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008; 8:1461-70.
17. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 2003; 22:2934-47.
18. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 2004; 101:15100-5.
19. Cheung CH, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP, Chang JY. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer 2009; 8:43.
20. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001; 4:303-13.
21. Andersen SS, Ashford AJ, Tournebize R, Gavet O, Sobel A, Hyman AA, Karsenti E. Mitotic chromatin regulates phosphorylation of Stathmin/Op18. Nature 1997; 389:640-3.
22. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23:2825-37.
23. Doxsey S. The centrosome - a tiny organelle with big potential. Nat Genet 1998; 20:104-6.
24. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005; 65:3671-81.
25. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008; 8:450-8.
26. Desai A, Mitchison TJ. Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997; 13:83-117.
27. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 2003; 116:2987-98.
28. Cassimeris L. The oncoprotein 18/stathmin family of microtubule destabilizers. Curr Opin Cell Biol 2002; 14:18-24.
29. Jeha S, Luo XN, Beran M, Kantarjian H, Atweh GF. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 1996; 56:1445-50. (Pubitemid 26080992)
30. 1 arrest in human cancer cells. Cancer Res 1995; 55:5187-90.
31. Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009; 15:1686-97.
32. Pan J, Quintas-Cardama A, Manshouri T, Giles FJ, Lamb P, Tefferi A, et al. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 2007; 21:1395-404.
33. Jin Y, Chen Q, Shi X, Lu Z, Cheng C, Lai Y, et al. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci 2009; 100:1335-43.
34. Boggs B, Cabral F. Mutations affecting assembly and stability of tubulin: evidence for a nonessential betatubulin in CHO cells. Mol Cell Biol 1987; 7:2700-7.
35. Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 1991; 266:3987-94. (Pubitemid 21909306)